Effects of <i>Lactobacillus rhamnosus</i> Strain GG in Pediatric Obesity‐related Liver Disease

Vajro, Pietro; Mandato, Claudia; Licenziati, Maria Rosaria; Franzese, Adriana; Vitale, Dino Franco; Lenta, S.; Caropreso, M.; Vallone, Gianfranco; Meli, Rosaria

doi:10.1097/mpg.0b013e31821f9b85

Cited by 306 publications

(214 citation statements)

References 30 publications

Supporting

Mentioning

199

Contrasting

Unclassified

Order By: Relevance

“…A double blind, placebo-controlled pilot study, on obese children showed that supplementation with probiotics showed no alteration in ultrasound liver parameters (27). In the current study, Ahmad Shavakhi et al reported that probiotics combined with Metformin decreased ultrasound grading of NASH significantly better than metformin alone in patients with NASH (41).…”

Section: Discussionmentioning

confidence: 49%

“…Our results with regards to reductions in liver aminotransferase are similar to those of Nabavi et al (26), who showed that probiotic yogurt for 8 weeks in patients with NAFLD caused a decrease in ALT and AST. In another study, probiotic supplementation in pediatric obesity-related liver disease for 8 weeks decreased ALT serum level (27). Also, a meta analysis study in 2016 reviewed efficacy of probiotics in nonalcoholic fatty liver disease in adult and children, in which a total of 9 clinical trial studies were included and reported significant differences in ALT, AST, and BMI between the 2 childhood groups (28).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

Javadi¹,

Ghavami²,

Khoshbaten³

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Oral administration of pro-and prebiotics has recently been considered as an effective way for nonalcoholic fatty liver disease (NAFLD) recovery. Objectives:The current study aimed at evaluating the effect of supplementation with probiotics and/or prebiotics on liver function tests in patients with NAFLD. Methods:In this double blind, placebo-control clinical trial, 75 subjects with NAFLD were voluntarily recruited from May 2013 to March 2014, in Iran. Participants were randomly assigned to 1 of 4 groups using a block randomization procedure. Group 1 received probiotic capsules (Bifidobacterium longum (BL) and Lactobacillus acidophilus (LA): 2 × 10 7 CFU/day), group 2 received prebiotic inulin high performance (HP): 10 g/day, group 3 received probiotic and the prebiotic, and group 4 received a placebo for 3 months. The sample size was determined on the basis of a primary outcome of a change in aspartate aminotransferase (AST) level.Results: An intergroup comparison indicated that the AST (P = 0.006) and alanine aminotransferase (ALT) (P = 0.04) levels decreased at the end of the study. Aspartate Aminotransferase (mean difference of group1 versus placebo with P value of 0.001, group2 versus placebo with P value of 0.045, group3 versus placebo with P value of 0.015) and ALT (mean difference of group 1 versus placebo with P value of 0.009, group 2 versus placebo with P value of 0.041, and group 3 versus placebo with P value of 0.046) serum levels decreased significantly in all of the intervention groups compared to the placebo. The grade of fatty liver in group 1 (P of 0.027, and number needed to treat (NNT) = 3) and group 3 (P = 0.019 and NNT = 3) decreased compared to the placebo group with no significant changes in group 2.Conclusions: Supplementation with probiotics and/or prebiotics improved aminotransferase enzymes, and supplementation with probiotics or pro-and prebiotics recovered the grade of fatty liver in NAFLD patients.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

Javadi¹,

Ghavami²,

Khoshbaten³

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

show abstract

“…In an RCT performed by Vajro et al on obese children treated with Lactobacillus GG for 8 weeks, a significant decrease in ALT was reported (34). In RCT of VSL#3, "a mixture of eight probiotic strains" compare to placebo in overweight children with biopsy-proven NAFLD, administration of VSL#3 for 4 months significantly improves NAFLD in children (27).…”

Section: Discussionmentioning

confidence: 98%

Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review

Shahmirzadi

Barati

2017

J Pediatr Rev

View full text Add to dashboard Cite

Context: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver illness that results from exceeding fat cumulating in the liver. NAFLD can result in progressive fibrosis, which leads to end-stage liver disease. It has rapidly evolved into the most common liver disease seen in the pediatric and adolescent population, being an increasingly common indication for liver transplant even in youths. Best practices in the management of pediatric NAFLD have not been clearly defined.Objectives: Due to increasing prevalence and the nature of the disease as well as importance of treatment plans and efficacy of each mode of treatment, all studies for pediatric fatty liver disease have been investigated for introducing definite or potential therapies. Data Sources:This systematic review aimed to include and analyze all studies descry the effectiveness of lifestyle modification, pharmacological, non-pharmacological, and dietary supplement treatments in children suffered from fatty liver, NAFLD, or NASH. The PUBMED/MEDLINE for Controlled Trials, Scopus, and OVID databases were searched for articles published up to and including December 2016.Study Selection, Data Extraction: All study in the pediatric group with diagnosis of fatty liver spectrum were included in this review. Adult studies were excluded. The results extracted and expanded.Results: A total of 27 randomized controlled trials were identified after the complete search, deletion of duplicates, removal of irrelevant studies, and final assessment of studies. Treatment plans of interest in these pediatrics articles included: lifestyle modifications, fish oil, and omega-3 fatty acids, including docosahexaenoic acid (DHA), probiotics, vitamin E, metformin, ursodeoxycholic acid, vitamin D, and bariatric surgery. Conclusions:Lifestyle modification is the only approved treatment modality for which evidence-based studies have documented benefits. Omega-3 fatty acids, particularly DHA, are probably effective. Probiotics likely have therapeutic effects in cases of fatty liver; however, further research is needed. Vitamin E and metformin have equivocal results. Ursodeoxycholic acid is recommended as an adjuvant; however, the data are insufficient for vitamin D. Bariatric surgery is not an acceptable plan in pediatric patients. Research of fatty liver diseases in children in all aspects of treatments is urgently needed.

show abstract

“…They found that 4-month supplement of VSL#3 significantly improved the liver function and increased GLP-1/ aGLP1 levels suggesting the beneficial effects of VSL#3 might be GLP-1-dependent [104]. Similarly, consistently beneficial effects were also observed on children with obesity and NAFLD by administering probiotics such as Lactobacillus rhamnosus strain GG [105] and mixed bacteria of Lactobacillus bulgaricus and Streptococcus thermophilus [106]. Sepideh, A et al investigated the effects of a multistrain probiotic supplementation in NAFLD patients in a RCT study [107], and the results showed dramatic improvement in insulin sensitivity and inflammation.…”

Section: Gut Microbiota-targeted Therapies Of Nafldmentioning

confidence: 97%

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Ma¹,

Zhou²,

Li³

2017

Preprint

View full text Add to dashboard Cite

Gut microbiota play critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, and insulin resistance, which highlighted the potential of gut microbiota-targeted therapies on these diseases. There are various ways that can manipulate gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines. In this review, we first described the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies in NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiotatargeted therapies in the future.

show abstract

Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity‐related Liver Disease

Abstract: Probiotic L rhamnosus strain GG warrants consideration as a therapeutic tool to treat hypertransaminasemia in hepatopathic obese children noncompliant with lifestyle interventions.

Cited by 306 publications

References 30 publications

The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Contact Info

Product

Resources

About